Eltrombopag enhances platelet response in chronic ITP patients

06/10/2009 | Doctor's Guide

A Phase III trial showed that eltrombopag improved overall platelet responses compared with a placebo in patients with chronic idiopathic thrombocytopenic purpura [who were either splenectomized or not]. "This eltrombopag treatment not only provides results in the short term, but also provides sustained and durable responses," a researcher said.

View Full Article in:

Doctor's Guide

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR